NEW YORK (TheStreet) -- Tuesday featured two huge movers, with shares of Bluebird Bio (BLUE) up 57% and Conn's (CONN) down a whopping 40%. Let's starts with the good, said TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio.
On CNBC's "Cramer's Mad Dash" segment, Cramer explained that shares of Bluebird are higher due to the company's presentation at the American Society of Hematology conference in San Francisco.
The company manufactures a drug that boosts hemoglobin without the use of a blood transfusion. This could be a "miracle drug for sickle cell anemia," Cramer said.
There is a lot of exciting news and data from the hematology conference, "but Bluebird is probably the biggest winner of all," Cramer said.
Now for the bad news. Shares of Conn's are lower after the company disappointed investors with its third-quarter earnings results. The company grew revenues 19% year-over-year, but reported an enormous earnings-per-share miss, losing 8 cents per share in the quarter.
So even though shares of Conn's -- which was once a great growth story -- are trading at a large discount, investors should avoid the stock.
"There are too many question marks right now," Cramer said.
-- Written by Bret Kenwell
TheStreet Ratings team rates BLUEBIRD BIO INC as a Sell with a ratings score of D+. TheStreet Ratings Team has this to say about their recommendation:
"We rate BLUEBIRD BIO INC (BLUE) a SELL. This is driven by multiple weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and weak operating cash flow."
You can view the full analysis from the report here: BLUE Ratings Report